VELSIPITY

Growth

etrasimod

NDAORALTABLET
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
14

Clinical Trials (5)

NCT07470879Phase 2Not Yet Recruiting

A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

Started Mar 2026
24 enrolled
Colitis, Ulcerative
NCT07459686N/ANot Yet Recruiting

An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis

Started Mar 2026
553 enrolled
Ulcerative Colitis (UC)
NCT06398626N/ARecruiting

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

Started Sep 2024
300 enrolled
Colitis, Ulcerative
NCT06294925N/ARecruiting

A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis

Started May 2024
360 enrolled
Colitis, Ulcerative
NCT06140290Phase 1Completed

A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants

Started Dec 2023
8 enrolled
Healthy Participants

Loss of Exclusivity

LOE Date
Jun 21, 2036
125 months away
Patent Expiry
Jun 21, 2036
Exclusivity Expiry
Oct 12, 2028

Patent Records (5)

Patent #ExpiryTypeUse Code
9126932
Jul 22, 2029
U-3732
8580841
Mar 5, 2030
SubstanceProduct
12156866
Jan 6, 2036
U-4047
12377071
Jan 6, 2036
U-4255
11007175
Jan 6, 2036
U-3730